Active Biotech announced first patient dosed in amended HO172 study
The Phase Ib/II study evaluates tasquinimod in myelofibrosis patients refractory to JAK2 inhibitors, with greater dosing flexibility.
See the latest news and media coverage for Active Biotech. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotech company developing cancer and eye disease treatments
activebiotech.comLast updated
In short: Active Biotech advanced its tasquinimod clinical program in myelofibrosis and implemented a 1:100 reverse share split to consolidate capital.
The Phase Ib/II study evaluates tasquinimod in myelofibrosis patients refractory to JAK2 inhibitors, with greater dosing flexibility.
As of June 30, 2026, total shares and votes are 26,360,671.
The record date is June 4, 2026, and the last day of trading before the split is June 2.
The Meeting approved a 1:100 reverse share split, no dividend for 2025, re-elected board members, authorized share issues up to 30%, and amended the Articles' share limits.
Lund Sweden, July 24, 2026 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the Phase Ib/II clinical...
The Annual General Meeting in Active Biotech AB (publ) ("Active Biotech" or the "Company") held on May 20, 2026, resolved to carry out a reverse...
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated...
Active Biotech has received positive feedback from European regulatory authorities and ethics committees regarding the clinical proof-of-concept study...
Track Active Biotech and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Active Biotech and other trending companies.